DK1185615T3 - Rekombinante influenzavirus til vacciner og genterapi - Google Patents

Rekombinante influenzavirus til vacciner og genterapi

Info

Publication number
DK1185615T3
DK1185615T3 DK00920151T DK00920151T DK1185615T3 DK 1185615 T3 DK1185615 T3 DK 1185615T3 DK 00920151 T DK00920151 T DK 00920151T DK 00920151 T DK00920151 T DK 00920151T DK 1185615 T3 DK1185615 T3 DK 1185615T3
Authority
DK
Denmark
Prior art keywords
vaccines
gene therapy
influenza viruses
recombinant influenza
viruses
Prior art date
Application number
DK00920151T
Other languages
English (en)
Inventor
Yoshihiro Kawaoka
Gabriele Neumann
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1185615(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of DK1185615T3 publication Critical patent/DK1185615T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK00920151T 1999-04-06 2000-04-05 Rekombinante influenzavirus til vacciner og genterapi DK1185615T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (en) 1999-04-06 2000-04-05 Recombinant influenza viruses for vaccines and gene therapy

Publications (1)

Publication Number Publication Date
DK1185615T3 true DK1185615T3 (da) 2007-11-05

Family

ID=26826080

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07009953.6T DK1820853T3 (da) 1999-04-06 2000-04-05 Rekombinant influenzavirus til vacciner og genterapi
DK10011896.7T DK2345716T3 (da) 1999-04-06 2000-04-05 Rekombinante influenzavira til vacciner og genterapi
DK00920151T DK1185615T3 (da) 1999-04-06 2000-04-05 Rekombinante influenzavirus til vacciner og genterapi

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK07009953.6T DK1820853T3 (da) 1999-04-06 2000-04-05 Rekombinant influenzavirus til vacciner og genterapi
DK10011896.7T DK2345716T3 (da) 1999-04-06 2000-04-05 Rekombinante influenzavira til vacciner og genterapi

Country Status (19)

Country Link
EP (4) EP1820853B1 (da)
JP (3) JP5543048B2 (da)
KR (1) KR100702275B1 (da)
CN (2) CN1350578B (da)
AT (2) ATE525461T1 (da)
AU (1) AU4073300A (da)
BR (1) BRPI0009580B8 (da)
CA (2) CA2365526C (da)
CY (2) CY1108520T1 (da)
DE (6) DE122008000061I1 (da)
DK (3) DK1820853T3 (da)
ES (3) ES2290024T3 (da)
FR (1) FR11C0027I2 (da)
HK (2) HK1148778A1 (da)
IL (2) IL145702A0 (da)
MX (1) MXPA01010082A (da)
NL (2) NL300364I2 (da)
PT (2) PT1185615E (da)
WO (1) WO2000060050A2 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1820853B1 (en) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
DE122007000061I2 (de) * 1999-07-14 2011-07-21 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren.
WO2001083794A2 (en) 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
EP1862550A1 (en) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
UA92132C2 (ru) 2003-05-28 2010-10-11 Висконсин Алюмни Рисьёч Фаундейшн Высокоактивные рекомбинантные вирусы гриппа для вакцин и генотерапии
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
CA2568020C (en) 2004-05-25 2015-04-07 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP1814990A2 (en) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
EP1824990B1 (en) 2004-12-08 2015-02-18 MedImmune, LLC Methods of producing influenza vaccine compositions
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
CA2600730C (en) 2005-03-08 2014-11-25 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
WO2007146057A2 (en) * 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2049662A4 (en) 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CN102149405A (zh) 2008-07-11 2011-08-10 米迪缪尼股份有限公司 流感血凝素和神经氨酸酶变体
AU2009283557B2 (en) 2008-08-18 2013-01-17 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
AU2010213966B2 (en) 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US20140302077A1 (en) 2011-09-02 2014-10-09 Westfaelische Wilhelms-Universitaet Munester Live attenuated influenza virus
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
JP2018530314A (ja) * 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
WO2019046211A1 (en) * 2017-08-28 2019-03-07 Wisconsin Alumni Research Foundation NANOCAPSULES FOR THE ADMINISTRATION OF RIBONUCLEOPROTEINS
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
AU3760495A (en) * 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (en) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
EP1820853B1 (en) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy

Also Published As

Publication number Publication date
CY1112140T1 (el) 2015-11-04
FR11C0027I1 (fr) 2011-08-26
EP2345716B1 (en) 2015-01-14
EP1820853A2 (en) 2007-08-22
EP2910629B1 (en) 2018-09-19
DK1820853T3 (da) 2011-12-19
JP5543048B2 (ja) 2014-07-09
JP2011182797A (ja) 2011-09-22
ES2373405T3 (es) 2012-02-03
IL145702A (en) 2010-04-15
IL145702A0 (en) 2002-07-25
HK1214298A1 (zh) 2016-07-22
NL300364I2 (nl) 2017-08-03
CA2365526C (en) 2016-07-05
CN101851636B (zh) 2015-11-25
DK2345716T3 (da) 2015-02-09
DE122008000014I1 (de) 2011-12-01
NL300365I2 (nl) 2017-08-03
DE122011100037I1 (de) 2012-03-22
JP6224645B2 (ja) 2017-11-01
PT1820853E (pt) 2012-01-03
JP5775351B2 (ja) 2015-09-09
PT1185615E (pt) 2007-10-04
FR11C0027I2 (fr) 2021-12-31
HK1148778A1 (zh) 2011-09-16
BRPI0009580B8 (pt) 2021-05-25
EP1185615A2 (en) 2002-03-13
CN1350578A (zh) 2002-05-22
ES2290024T3 (es) 2008-02-16
WO2000060050A2 (en) 2000-10-12
EP1820853B1 (en) 2011-09-21
NL300364I1 (nl) 2009-01-05
JP2015119735A (ja) 2015-07-02
CY1108520T1 (el) 2014-04-09
DE60035778D1 (de) 2007-09-13
AU4073300A (en) 2000-10-23
ATE368729T1 (de) 2007-08-15
MXPA01010082A (es) 2002-04-24
BR0009580B1 (pt) 2014-11-25
CA2365526A1 (en) 2000-10-12
DE60035778T2 (de) 2008-04-30
JP2003528570A (ja) 2003-09-30
CN101851636A (zh) 2010-10-06
EP1820853A3 (en) 2007-10-03
DE122008000035I1 (de) 2009-05-20
CA2928263A1 (en) 2000-10-12
DE122008000058I1 (de) 2009-05-07
EP2910629A1 (en) 2015-08-26
ES2533622T3 (es) 2015-04-13
CN1350578B (zh) 2010-05-12
NL300365I1 (nl) 2009-01-05
KR20010113044A (ko) 2001-12-24
WO2000060050A3 (en) 2001-01-18
EP2345716A1 (en) 2011-07-20
ATE525461T1 (de) 2011-10-15
KR100702275B1 (ko) 2007-03-30
BR0009580A (pt) 2002-01-02
DE122008000061I1 (de) 2009-02-12
EP1185615B1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
DK1185615T3 (da) Rekombinante influenzavirus til vacciner og genterapi
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
FR20C1016I1 (da)
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
UA85536C2 (en) Viral antigens
DK1085904T3 (da) Svækkede minusstreng-vira med ændret interferon-antagonist-aktivitet til anvendelse som vacciner og lægemidler
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
FI964784A (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
FI893346A (fi) Icke-reverterande rna-virus.